0001564590-22-007338 Sample Contracts

INDEMNIFICATION AGREEMENT
Indemnification Agreement • February 28th, 2022 • Reata Pharmaceuticals Inc • Pharmaceutical preparations

This Agreement (“Agreement”) is made and entered into as of the 7th day of July, 2020, by and between Reata Pharmaceuticals, a Delaware corporation (the “Company”), and Samina Khan (“Indemnitee”).

Sample 1Sample 2Sample 3See All (38)
AutoNDA by SimpleDocs
EMPLOYMENT AGREEMENT by and between Reata Pharmaceuticals, Inc. and Samina Khan
Employment Agreement • February 28th, 2022 • Reata Pharmaceuticals Inc • Pharmaceutical preparations • Texas

THIS EMPLOYMENT AGREEMENT (the “Agreement”) is made and entered into as of the 7th day July of 2020, by and between Reata Pharmaceuticals, Inc., a Delaware corporation (together with its successors and assigns permitted hereunder, the “Company”), and Samina Khan (the “Executive”).

Sample 1Sample 2Sample 3See All (17)
LEASE AMENDMENT NO. 13
Reata Pharmaceuticals Inc • February 28th, 2022 • Pharmaceutical preparations

THIS LEASE AMENDMENT NO. 13 (this “Amendment”) is made and entered into effective as of February 4, 2022 (the “Effective Date”) by and between SDCO GATEWAY COMMERCE I & II, INC., a Delaware corporation (“Landlord”), and REATA PHARMACEUTICALS, INC., a Delaware corporation (“Tenant”).

Sample 1
Contract
Patent License Agreement • February 28th, 2022 • Reata Pharmaceuticals Inc • Pharmaceutical preparations

Specific terms in this Exhibit have been redacted because such terms are both not material and are of the type that the Company treats as private or confidential. These redacted terms have been marked in this Exhibit with three asterisks [***].

Sample 1
COLLABORATION AGREEMENT between REATA PHARMACEUTICALS, INC. and ABBOTT PHARMACEUTICALS PR LTD. Dated as of December 9, 2011
Collaboration Agreement • February 28th, 2022 • Reata Pharmaceuticals Inc • Pharmaceutical preparations • New York

Specific terms in this Exhibit have been redacted because such terms are both not material and are of the type that the Company treats as private or confidential. These redacted terms have been marked in this Exhibit with three asterisks [***].

Sample 1
FOURTH SUPPLEMENT TO EXCLUSIVE LICENSE AND SUPPLY AGREEMENT Regarding Milestone payments, Supply price and Products manufacturing
Fourth Supplement to Exclusive License and Supply Agreement • February 28th, 2022 • Reata Pharmaceuticals Inc • Pharmaceutical preparations

This Fourth Supplement (herein so called), effective as of December 6, 2017 (the “Supplement Effective Date”), to the Exclusive License and Supply Agreement, effective as of December 24, 2009 (the “Original Agreement”), is by and between Reata Pharmaceuticals, Inc., a corporation organized and existing under the laws of Delaware, USA, with an address at 2801 Gateway Drive, Suite 150, Irving, Texas 75063 (“Reata”), and Kyowa Hakko Kirin Co., Ltd., a company organized and existing under the laws of Japan, with an address at 1-9-2 Ohtemachi, Chiyoda-ku, Tokyo, 100-0004, Japan (“Kyowa Kirin”). Reata and Kyowa Kirin are sometimes hereinafter referred to each as a “Party” and collectively as the “Parties”.

Sample 1
THIRD SUPPLEMENT TO EXCLUSIVE LICENSE AND SUPPLY AGREEMENT Regarding Phase 3 Clinical Study (Alport Syndrome) in Japan
Exclusive License and Supply Agreement • February 28th, 2022 • Reata Pharmaceuticals Inc • Pharmaceutical preparations

This Third Supplement (herein so called), effective as of December 6, 2017 (the “Supplement Effective Date”), to the Exclusive License and Supply Agreement, effective as of December 24, 2009 (the “Original Agreement”), is by and between Reata Pharmaceuticals, Inc., a corporation organized and existing under the laws of Delaware, USA, with an address at 2801 Gateway Drive, Suite 150, Irving, Texas 75063 (“Reata”), and Kyowa Hakko Kirin Co., Ltd., a company organized and existing under the laws of Japan, with an address at 1-9-2 Ohtemachi, Chiyoda-ku, Tokyo, 100-0004, Japan (“Kyowa Kirin”). Reata and Kyowa Kirin are sometimes hereinafter referred to each as a “Party” and collectively as the “Parties”.

Sample 1
EXCLUSIVE LICENSE and SUPPLY AGREEMENT by and between REATA PHARMACEUTICALS, INC. and KYOWA HAKKO KIRIN CO. LTD.
Exclusive License and Supply Agreement • February 28th, 2022 • Reata Pharmaceuticals Inc • Pharmaceutical preparations • Delaware

This Exclusive License and Supply Agreement (this “ Agreement ”) effective as of December 24, 2009 (the “ Effective Date ”), is by and between Reata Pharmaceuticals, Inc., a corporation organized and existing under the laws of Delaware, USA, with an address at 2801 Gateway Drive, Suite 150, Irving, Texas 75063 (“ Reata ”), and Kyowa Hakko Kirin Co., Ltd., a company organized and existing under the laws of Japan, with an address at 1-6-1 Ohtemachi, Chiyoda-ku, Tokyo, 100-8185, Japan (“ Kyowa Kirin ”). Reata and Kyowa Kirin are sometimes hereinafter referred to each as a “ Party ” and collectively as the “ Parties .”

Sample 1
Contract
License Agreement • February 28th, 2022 • Reata Pharmaceuticals Inc • Pharmaceutical preparations • New York

Specific terms in this Exhibit have been redacted because such terms are both not material and are of the type that the Company treats as private or confidential. These redacted terms have been marked in this Exhibit with three asterisks [***].

Sample 1
REATA PHARMACEUTICALS, INC. DARTMOUTH EXCLUSIVE LICENSE AGREEMENT
Dartmouth Exclusive License Agreement • February 28th, 2022 • Reata Pharmaceuticals Inc • Pharmaceutical preparations • Delaware

This Agreement, effective this 16th day of December 2009, between TRUSTEES OF DARTMOUTH COLLEGE, a non-profit educational and research institution existing under the laws of the State of New Hampshire, and being located at Hanover, New Hampshire 03755, hereinafter called Dartmouth, and REATA PHARMACEUTICALS. INC., a corporation of the State of Texas, with a principal place of business at 2801 Gateway Drive, Suite 150, Irving, Texas 75063; hereinafter called Company or Reata.

Sample 1
EXCLUSIVE LICENSE AGREEMENT between Reata Pharmaceuticals, Inc. and KU Center for Technology Commercialization, Inc. Exclusive License Agreement
License Agreement • February 28th, 2022 • Reata Pharmaceuticals Inc • Pharmaceutical preparations • Kansas

THIS LICENSE Agreement (“Agreement”) is entered into this 26th day of September, 2014 by and between the KU CENTER FOR TECHNOLOGY COMMERCIALIZATION, INC, a Kansas non-profit § 501(c)(3) corporation, having its principal place of business at 3901 Rainbow Boulevard, Kansas City, Kansas 66160, hereinafter referred to as “KUCTC” or “Licensor,” and “REATA PHARMACEUTICALS, INC.” having its principal place of business at 2801 Gateway Drive, Suite 150, Irving, Texas 75063, hereinafter referred to as “Licensee.”

Sample 1
Time is Money Join Law Insider Premium to draft better contracts faster.